Solvonis Therapeutics plc

0.10pAs of Sun 8 Nov 2026, 12:00 UTC
LSE:SVNSHealthcare
Ctry United Kingdom
PE (Fwd) •••
TSR 5Y CAGR (68.07%)
Div yield —
ROE (94.61%)
Biotechnology
Beta (5Y) 1.22
PE TTM —
TSR TTM (69.35%)
Mkt cap £6.466M
ROIC (35.68%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
0.103p
8.72%
(30.13%)
Hold 3|7|5|8|0
4Q25
1Q26
2Q26
3Q26
Earnings per share£
—
—
—
—
37.06%
38.84%
42.62%
39.88%
Revenue£M
0.755
0.775
0.755
0.752
(4.25%)
(1.78%)
(5.30%)
(3.05%)
Peers (US$8.563M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.720
0.050
0.045
EBIT/Intx
1.275
0.129
0.127
Own earn%
(50.31)
(8.66)
(7.11)
Sh yield%
35.41
41.51
42.04
Owners
Insiders/Inst%
13.82
41.56
Short interest%
1.62
SBC / revenue%
3.42
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
13
Op margin range%
18–21
$1 testx
—
Incr. ROIC%
9